Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma. Medical affairs is evolving. Once primarily viewed as a support function in ...

China said it will take “resolute measures” to defend its trading rights, but gave no details on how it will respond to U.S.

European Union member states have voted to approve retaliatory tariffs on $23 billion in goods in response to U.S. President ...

Find insight on Sartorius, China’s healthcare industry and more in the latest Market Talks covering health care.

North American markets are mixed this morning as traders operate under the shadow of newly announced retaliatory tariffs from ...

Facing a global market meltdown, President Donald Trump on Wednesday abruptly backed down on his tariffs on most nations for ...

The U.S. stock market is shaking through twitchy trading Wednesday after most other markets tumbled as President Donald Trump ...

Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., Sarepta and Roche have ... told Fierce Pharma last month.